Global Peptide and Anticoagulant Drugs Market Outlook 2022

Peptide and Anticoagulant Drugs can be used to prevent endovascular embolism or thrombosis, stroke or other thrombotic diseases. It is a drug that prevents coagulation by affecting certain coagulation factors in the process of coagulation.

The global Peptide and Anticoagulant Drugs market was valued at US$ 463.9 million in 2020 and is expected to reach US$ 826.7 million by the end of 2027, growing at a CAGR of 8.5% during 2021-2027.
This report focuses on Peptide and Anticoagulant Drugs volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Peptide and Anticoagulant Drugs market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.

Global Peptide and Anticoagulant Drugs Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type
Hormonal
Antibiotic
ACE Inhibitor
Antifungal
Others

Segment by Application
Diabetes
Infectious Diseases
Cancer
Osteoporosis
Cardiology
Gynecology
Other Applications

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

By Company
Celsus
Baxter
Hemmo Pharma
Biofer
Wockhardt
AmbioPharm
Bachem
Sun Pharmaceutical Industries
Pfizer
Abbott Laboratories
Leo Pharma
Aspen
Takeda
Teva
Sanofi
Eli Lilly
Novo Nordisk